Type 2 diabetes, once a rare affliction of the affluent and elderly, now affects hundreds of millions worldwide and ranks among the most pressing public health challenges of the 21st century. Characterized by insulin resistance and relative insulin deficiency, it accounts for 90-95% of diabetes cases. Unlike the more dramatic, insulin-dependent form (now called Type 1), Type 2 often develops gradually, intertwined with lifestyle, obesity, and aging. Its history spans over 3,500 years, evolving from vague descriptions of “honey urine” in ancient texts to sophisticated understandings of metabolic dysfunction.
This post traces that journey, highlighting key milestones, scientific breakthroughs, and the societal shifts that turned a niche condition into a global crisis.
Ancient Roots: Sweet Urine and Wasting Flesh
The earliest known references to diabetes-like symptoms appear in the Ebers Papyrus, an Egyptian medical text from around 1550 BCE. It describes a condition involving excessive urination (“too great emptying of urine”), which doctors attempted to treat with herbal mixtures, though success was limited.
Ancient Indian physicians provided more detailed accounts. Around the 5th-6th century BCE, Sushruta and Charaka documented madhumeha (“honey urine”) in Sanskrit texts. They noted that the urine attracted ants and flies due to its sweetness and distinguished two forms: one affecting thinner, younger individuals (akin to Type 1) and another linked to obesity and sedentary habits in older, wealthier people—remarkably prescient for what we now call Type 2. Treatments included diet, exercise (especially on horseback), and herbal remedies.
In ancient Greece, Apollonius of Memphis coined the term diabetes (from the Greek for “siphon” or “to pass through”) around 250 BCE, capturing the excessive fluid loss. Aretaeus of Cappadocia (2nd century CE) offered the first vivid clinical description: “Diabetes is a strange affliction… a melting down of the flesh and limbs into urine.” He portrayed unquenchable thirst, incessant urination, and a short, painful life—symptoms that align closely with uncontrolled diabetes today.
Chinese and Arab physicians also recognized the condition. Avicenna (980–1037 CE) in The Canon of Medicine described abnormal appetite, diabetic gangrene, and even suggested treatments with seeds like lupin and fenugreek. These early observers grasped the disease’s wasting nature but lacked tools to measure blood sugar or understand its pancreatic origins.
Medieval to Renaissance: Observation and Early Experiments
During the Middle Ages, diabetes remained rare and poorly understood in Europe. Islamic Golden Age scholars built on Greek and Indian knowledge, emphasizing dietary management. In the 17th century, English physician Thomas Willis (1621–1675) revived interest by tasting patients’ urine and noting its sweetness, adding mellitus (Latin for “honeyed”) to distinguish it from diabetes insipidus (tasteless urine). This bedside “test” became a diagnostic hallmark.
Matthew Dobson in 1776 confirmed that the sweetness came from sugar in both blood and urine, linking it to elevated blood glucose. By the late 18th century, John Rollo advocated low-carbohydrate diets for management, a precursor to later approaches.
19th Century: Pancreatic Link and Emerging Science
The 1800s brought systematic study. Claude Bernard’s work on glycogen and liver metabolism laid groundwork for understanding glucose regulation. In 1889, Oskar Minkowski and Joseph von Mering removed a dog’s pancreas, inducing severe diabetes. This proved the pancreas’s central role, shifting focus from vague humoral theories to organ-specific pathology.
Paul Langerhans had described pancreatic “islets” in 1869, but their function was unclear until Édouard Laguesse suggested in 1893 they regulated digestion and metabolism. These discoveries set the stage for the insulin era, though Type 2’s insulin resistance remained unrecognized.
Early 20th Century: Insulin Revolution and the Split Between Types
The landmark 1921 discovery of insulin by Frederick Banting, Charles Best, John Macleod, and James Collip in Toronto transformed diabetes from a near-death sentence to a manageable condition. Purified extracts saved lives, earning Banting and Macleod the 1923 Nobel Prize. Initially hailed as a cure, it proved more effective for what we now call Type 1.
In the 1930s, researchers noted many patients—often older and overweight—produced insulin but responded poorly to it. Harold Himsworth in 1936 distinguished “insulin-sensitive” (Type 1) from “insulin-insensitive” (Type 2) diabetes. Rosalyn Yalow and Solomon Berson’s 1959 radioimmunoassay confirmed Type 2 patients had normal or high insulin levels, proving resistance rather than deficiency as the core issue.
This distinction clarified why diet and exercise helped many Type 2 cases, while insulin was lifesaving for Type 1.
Mid-20th Century: Oral Medications and Lifestyle Insights
The 1950s introduced oral drugs for Type 2. Sulfonylureas (e.g., carbutamide in 1955) stimulated insulin release. Biguanides like metformin, derived from the French lilac (Galega officinalis), gained traction; its glucose-lowering effects were known since the 1920s but repurposed safely in the 1950s. Metformin remains first-line therapy today due to its efficacy, weight neutrality, and cardiovascular benefits.
Post-WWII prosperity brought dietary shifts: more processed foods, sugars, and sedentary jobs. Obesity rates climbed, driving Type 2 prevalence. Studies linked excess weight, especially central obesity, to insulin resistance.
Late 20th Century: Genetic Insights, New Drugs, and the Rising Epidemic
The 1970s–1990s saw receptor research (e.g., C. Ronald Kahn on insulin resistance) and genetic studies. Over 70 genes now link to Type 2 risk, interacting with environment. Thiazolidinediones (“glitazones”) in the late 1990s improved insulin sensitivity but faced safety issues (e.g., troglitazone withdrawal).
Meanwhile, the epidemic accelerated. Global cases rose dramatically due to urbanization, aging populations, reduced activity, and obesity. From roughly 200 million in 1990 to over 800 million by the early 2020s, Type 2 dominates in low- and middle-income countries. In the U.S., prevalence exceeds 12%, with higher rates among certain ethnic groups.
21st Century: Precision Medicine, Technology, and Prevention
Today, management integrates continuous glucose monitors (CGM), insulin pumps (adapted for Type 2), AI-driven insights, and multifaceted drugs. Lifestyle interventions—like the Diabetes Prevention Program—show up to 58% risk reduction through modest weight loss and activity. Remission via very-low-calorie diets or surgery is achievable for some.
Challenges persist: progression over time often requires escalating therapy, and disparities in access widen outcomes. Inflammation, beta-cell dysfunction, and gut microbiome roles add complexity. Emerging therapies target these, alongside gene editing and brown fat activation.
Societal and Future Perspectives
Type 2 diabetes reflects modern life: abundant calories, screen time, and stress. Prevention demands policy changes—urban planning for activity, food system reforms, and early screening. Education empowers individuals: balanced diets, regular movement, and weight management yield profound effects.
Looking ahead, integration of genomics, wearables, and personalized nutrition promises tailored care. With global projections nearing 850 million by 2050, collective action is essential.
Conclusion
From ants swarming honeyed urine in ancient India to GLP-1 drugs reshaping metabolism, the history of Type 2 diabetes mirrors humanity’s scientific progress and lifestyle evolution. What began as a mysterious wasting disease is now a preventable, manageable metabolic disorder—for many. Yet its rise warns of environmental costs.
Understanding this history inspires hope: each era built on prior knowledge, turning fatal diagnoses into chronic conditions with long and fulfilling lives. Continued research, public health vigilance, and personal responsibility can curb the epidemic, ensuring future generations experience healthier outcomes.